Blood therapy giant CSL reports better than expected NPAT | CSL (ASX:CSL) Reporting Results

Jessica Amir
August 18, 2021

The biggest blood therapy company in the world and the second biggest vaccine company, CSL (ASX:CSL) reported its FY21 results.

CSL reported its NPAT jumped 13% to US$2.375 billion. This is 2% above market expectations. Profit growth was boosted by CSL’s Seqirus division, its flu vaccine business, which saw a 30% revenue boost. However, CSL’s Behring division, its blood therapy business, was severely impacted by COVID-19 restrictions.

CSL’s group revenue rose 13% to US$10.3 billion, while CSL’s cashflow from operations surged 46% to US$3.6 billion.

CSL declared a final dividend of US$1.18ps (AU$1.61ps), payable on 30th September. CSL’s total full year dividends increased 10% to US$2.22 per share.

CSL’s FY22 outlook views profit to fall between US$2.15 billion to US$2.25 billion.

CSL is a Morgan Stanley, Macquarie, Citi and Credit Suisse HOLD stock. UBS and Morgans have CSL as a BUY stock.

CSL shares surged to $302.80, at its highest level since June. However, traders quickly took profits, and CSL is now trading at $294.83.

Weekly Wrap 22 October

Sophia Mavridis
October 22, 2021

Morning Bell 21 October

Paulina Peters
October 21, 2021

Morning Bell 20 October

Jessica Amir
October 20, 2021

Morning Bell 19 October

Jessica Amir
October 19, 2021

Morning Bell 18 October

Jessica Amir
October 18, 2021

Weekly Wrap 15 October

Jessica Amir
October 15, 2021

Morning Bell 15 October

Paulina Peters
October 15, 2021

Morning Bell 14 October

Jessica Amir
October 14, 2021

Morning Bell 13 October

Jessica Amir
October 13, 2021

Morning Bell 12 October

Sophia Mavridis
October 12, 2021

Morning Bell 11 October

Jessica Amir
October 11, 2021

Weekly Wrap 8 October

Jessica Amir
October 8, 2021